April 23rd 2021
The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.
Amgen Posts Updates on Triplet Therapy Using Carfilzomib
September 17th 2019Amgen recently announced early phase 3 CANDOR study data, showing the triple-drug combination of carfilzomib (Kyprolis), along with dexamethasone and daratumumab (Darzalex, sold by Janssen), met its primary end point of progression-free survival in patients with relapsed or refractory multiple myeloma, with a 37% reduction in the risk of progression or death.
Read More
Dr Ajai Chari Discusses the Importance of Real-World Evidence in Multiple Myeloma
September 11th 2019Real-world outcomes are important because the populations included in clinical trials rarely reflect the populations actually being treated in the clinic, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Watch
New Liquid Biopsy Test Found to Identify Patients Who May Respond to Immune Checkpoint Blockade
September 10th 2019A new liquid biopsy test could detect microsatellite instability and tumor mutational burden, which can distinguish which patients are likely to respond to immune checkpoint inhibitors.
Read More
Dr John Fox Discusses Financial Toxicity Associated With Multidrug Regimens for Multiple Myeloma
August 29th 2019With an increase in the use of 3- and 4-drug regimens in multiple myeloma, providers are going to need to communicate the out-of-pocket costs when presenting treatment options so that patients can make an informed decision, explained John Fox, MD, MHA, vice president of Clinical Transformation at Spectrum Health.
Watch
Dr Ajai Chari Outlines Disparities and Treatment Patterns in Multiple Myeloma
August 24th 2019Research has shown disparities in multiple myeloma treatment between clinical trials and real-world outcomes, as well as a lot of heterogeneity among treatment patterns by age and region, said Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital.
Watch
Patients With Low-Risk Multiple Myeloma Precursor Can Progress to the Disease in Just 5 Years
August 10th 2019Patients with monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma (MM), can progress from low- or intermediate-risk to MM in just 5 years, according to researchers who are now recommending all patients with MGUS undergo blood testing and risk assessment.
Read More
Researchers Identify 5 Risk Factors for Blood Clots in Patients With MM Treated With IMiDs
July 19th 2019Venous thromboembolism (VTE) is a significant complication for patients with multiple myeloma (MM) who are being treated with immunomodulatory drugs (IMiDs), and a new assessment model may help to predict VTE in this population.
Read More
Dova Pharmaceuticals Launching Avatrombopag for Chronic Immune Thrombocytopenia
July 13th 2019With the FDA approval of a supplemental New Drug Application (sNDA) expanding the use of avatrombopag (Doptelet) for patients with chronic immune thrombocytopenia (ITP), Dova Pharmaceuticals said recently it will begin marketing the drug for the new indication in the middle of July.
Read More